22 Sep 2005

European Commission Approves Use of UCB's Anti-Epileptic Keppra® as Adjunctive Therapy in Children Four Years of Age and Older with Partial-Onset Seizures

Read More
15 Sep 2005

UCB'S ANTI-EPILECTIC KEPPRA® MEETS PRIMARY END-POINT IN MONOTHERAPY TRIAL

Read More
26 Aug 2005

UCB Announces Divestment of Celltech Manufacturing Services - a UCB Subsidiary for Contract Manufacturing

Read More
16 Aug 2005

UCB And Imclone Systems Enter Into Worldwide Partnership For Cdp-791, A Novel Investigational Therapy Targeting The Development Of Tumor Vasculature

Read More
1 Aug 2005

UCB Reports Positive Opinion from EMEA for Paediatric Indication for Keppra®

Read More
27 Jul 2005

UCB first half-year 2005 results including unaudited Half-Year Financial Report

Read More
27 Jul 2005

UCB first half-year 2005 results

Read More
26 Jul 2005

CIMZIA(TM) demonstrates significant positive results in its two pivotal phase III Crohn's disease trials

Read More
25 Jul 2005

UCB Receives Positive Opinion from European Authorities for Orphan Designation of Brivaracetam for the Treatment of Progressive Myoclonic Epilepsies

Read More
20 Jul 2005

UCB Confirms Solid First Half Zyrtec Sales in USA

Read More
Subscribe to